In contrast, HER2-positive and triple-negative breast cancers undergo NAC not only in the locally advanced stage but also in earlier stages, with pCR rates being significantly higher, up to 40–60%. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.